Skip to content
inentertainment.co.uk
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
RIGEL PHARMACEUTICALS, INC.
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
August 14, 2026
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
August 13, 2026
Rigel Reports Second Quarter 2026 Financial Results
August 4, 2026
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
July 28, 2026
Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
July 1, 2026
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
June 16, 2026
Rigel to Present at the Jefferies Global Healthcare Conference
May 27, 2026
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
May 26, 2026
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
May 24, 2026
Rigel Reports First Quarter 2026 Financial Results
May 23, 2026
1
2
Next Page
→